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Part 1: Introduction 
1.1 Oral cancer is a leading cause of death 
Cancer is a leading cause of death. In 2008, it caused 7,6 million deaths worldwide – a 
number which is estimated to reach 13,1 million in 2030. [1] Amidst the cancer-related 
deaths, oral cancer is ranked the eighth most common; its 5-year survival rate is only 50 
percent. Over 90 percent of the oral cancers are, in fact, oral squamous cell carcinomas 
(OSCC). [2, 3] 
This master thesis will focus on the work I completed together with my mentors Professor 
Trond S. Halstensen and Ph.D-candidate Gao Jian. The work relates to Gao Jian’s studies on 
cisplatin-resistance in OSCC. She induced cisplatin resistance in previously sensitive cell 
lines to examine the intracellular mechanisms for drug resistance. During this work she 
discovered that the Amphiregulin mRNA levels varied in a cyclic manner. 
Although cyclic mRNA fluctuation is the main topic, the thesis will include an introduction of 
basic elements which relate to the treatment of OSCC – beginning with the chemotherapeutic 
drug cisplatin; a platinum-based drug also known as cis-diamminedichloroplatinum (II). [4] 
1.2 Cisplatin – the chemotherapeutic miracle? 
Cisplatin was first used to treat cancer in 1971. [4, 5] Today, it is still the drug of choice when 
treating a wide variety of malignant solid tumors, primarily of the testes, ovaries, urine 
bladder, esophagus and head and neck squamous cell carcinoma (HNSCC). [5, 6] It is one of 
the most effective broad-spectrum anticancer drugs [7] and can be used either alone or in 
combination with other drugs and adjuvant treatments. [5] For HNSCC, it is often combined 
with radiotherapy. [8]  
The mechanism of cisplatin is mainly through its platinum contents, which form covalent 
bonds to DNA purine bases, creating DNA adducts. [4] The DNA adducts cause structural 
changes of the DNA – e.g. through bending and unwinding – which leads to inhibition of 
DNA replication and RNA transcription. This ultimately leads to cellular apoptosis. [4, 9] The 
precise cellular mechanisms of the platinum-DNA adducts’ induction of cell death are not yet 
fully understood. [9] 
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1.3 Treatment resistance 
The most prevalent clinical problem of cisplatin is the development of tumor resistance, a 
feature which becomes evident when cancer cells do not undergo apoptosis at clinically 
relevant drug concentrations. [9] The mechanisms of cisplatin-resistance are divided into two 
main categories: “Intrinsic resistance”, which describes resistance in previously untreated 
tumor cells and “acquired resistance”, in which repeated exposure to cisplatin triggers 
resistance. [5]  
The potency of cisplatin is complex due to its many routes of entry and multiple cellular 
pathways, therefore allowing the development of cisplatin resistance to occur through equally 
complex changes in gene expression. [7] Many studies have been conducted to better 
understand the mechanisms of drug resistance, in hope of eventually increasing cisplatin 
efficiency by combining it with resistance modulators. [4] 
1.4 Studying the molecular pattern of resistance 
Squamous cell carcinomas (SCC) derive from keratinocytes. Amphiregulin (AREG) is a 
growth factor in the epidermal growth factor (EGF) family and is an established oncogene in 
epithelial malignancies. [10] In this paper, we have studied the levels of AREG in different 
cisplatin resistant oral cancer cell lines, but before looking at the methods and results; let us 
begin by better understanding the target molecule, amphiregulin. 
1.5 The answer might be in amphiregulin 
Several recent publications have identified AREG as a key factor for cisplatin resistance in 
human breast cancer. [11, 12] Eckstein et al. discovered a significant correlation suggesting 
that breast cancer cells used AREG as a survival signal upon exposure to cisplatin. [11] 
However, this was not observed for lung cancer cells – samples did not show a connection 
between cisplatin resistance and amphiregulin expression, despite elevated amphiregulin-
levels. At the very end they state: 
“[…]it is necessary to systematically investigate different tumor types to 
determine the role of amphiregulin for cisplatin resistance in other malignant 
tumors besides breast cancer.” (Eckstein et al.) [11] 
There is a lot of interest in how AREG may be involved in the development of cisplatin 
resistance. It has been suggested that AREG-expression has a tumor promoting capability 
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for oral squamous cell carcinomas (OSCC). [13] Many researchers believe that this gene 
may be a target for future resistance modulating chemotherapeutic drugs!  
1.6 Amphiregulin 
Amphiregulin (AREG) is a protein, originally identified in the human breast carcinoma cell 
line MCF-7. [15] AREG is an 84-amino acid glycoprotein which, in its mature form, has a 
three-looped secondary structure. [10] This mature form is due to six cysteines, in the 
polypeptide chain, which constitute three disulfide linkages conserved in all the EGF family 
ligands. [16] It is a ligand which binds and activates the epidermal growth factor receptor 
(EGFR). [10, 12] 
 
 
 
 
 
 
 
 
 
 
The name – amphiregulin – is given due to this growth factor’s ability to act stimulatory on 
certain cells and inhibitory on others. [12] AREG was previously recognized for its ability to 
inhibit growth of human carcinoma cells in culture and stimulate proliferation of human 
fibroblasts. [15] In newer literature, it has been recognized as an oncogenic factor. [10, 13] Its 
overexpression has been identified in HNSCC and in a wide variety of other human cancer 
tissues. [10, 16] The study which first identified this phenomenon concludes that there is a 
significant auto- and cross-induction among the different EGFR ligands, suggesting that it is 
not only AREG that could have tumor-promoting abilities. [16] 
 
Figure 1: The secondary structure of human amphiregulin. The six black C’s 
represent cysteines which join together, forming three disulfide links and three 
loops. This structure is conserved in other EGF family ligands. [14] 
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1.7 The EGFR family 
The EGFR belongs to a group of receptor tyrosine kinases known as the ErbB or human 
epidermoid receptor (HER) family. [10, 12] This receptor family contains four members: 
EGFR/ErbB1/HER1, ErbB2/HER2/Neu, ErbB3/HER3 and ErbB4/HER4. [10, 17] The 
ligands which bind to the ErbB receptor family are: amphiregulin (AREG/AR), epidermal 
growth factor (EGF), transforming growth factor alpha (TGF-α), heparin-binding EGF-like 
ligand (HB-EGF), betacellulin (BTC), epiregulin (EREG), epigen (EPGN) and neuregulin 
(NRG) family members. [11] All these ligands belong to the EGF family. [11] The mature 
form of AREG shares a structural homology with other ligands in the EGF family and all the 
ligands share at least 28 percent sequence identity. [10, 16] 
 
 
Figure 2: The ErbB-receptor family and ligands. After activation by a ligand, this is the 
resulting receptors after dimerization of the individual receptor tyrosine kinases. The 
conformational changes which occur along with dimerization activate different intracellular 
pathways depending on the many homo- and hetero-dimerizations. [18] 
The receptors in the ErbB-family share a structural homology. [10] They are single-pass, 
transmembrane receptor tyrosine kinases (RTKs). [19] The receptors are activated upon 
ligand-binding, which induces conformational changes in the extracellular domain. This 
facilitates the receptor’s homo- or hetero-dimerization with other family members [20], 
further resulting in the initiation of intracellular signaling cascades. Each EGF family ligand 
stabilizes different dimers and each dimer recruits different combinations of signaling 
molecules. [21] 
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1.8 The discovery of amphiregulin-fluctuations 
The complexity of the amphiregulin (AREG) molecule is what inspires scientists to study its 
mechanism – a fact which also applies for this thesis. When we first began studying cisplatin 
resistant and cisplatin sensitive cell lines, the aim was to explore whether there was a 
significant correlation between AREG-levels and cisplatin resistance. Upon working with 
these cells, it was discovered that the AREG-levels fluctuated with a seemingly consistent 
pattern over time. Whether these fluctuations were accurate or simply coincidental is the 
focus of this thesis. 
Before delving into the details of the laboratory work in parts 3 and 4; the next section will 
give a brief familiarization with certain expressions and include a bit of relevant theory.   
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Part 2: Genetics and background 
2.1 Gene expression 
The DNA codes our hereditary material, but only a portion of the DNA is actually expressed. 
The term ‘gene expression’ comprises the process of converting our DNA material into a 
product which has an effect on a cell or organism. [22] Protein synthesis is a major part of 
gene expression and to induce protein synthesis the messenger RNA (mRNA) needs to serve 
as a link. [23, 24] The mRNA carries the genetic information from the nucleus to the 
ribosomes in the cytoplasm, where it serves as the substrate for translation. [25] 
2.2 mRNA: Transcription and structure 
The basic layout of transcription contains the three steps: initiation, elongation and 
termination. During the initiation step, the enzyme RNA polymerase II (RNAPII) binds a 
specific sequence – the “promoter” – at the 5’ end (also termed “upstreams”) of a DNA 
template. After synthesizing approximately 10 nucleotides, the elongation process begins; the 
RNAPII enzyme synthesizes polynucleotides as encoded by the DNA, until it reaches a 
“termination signal”. In the termination step, RNAPII releases both the DNA template and 
RNA product. [22, 26] 
The mRNA molecule, just like DNA, has a 5’ and 3’ ends. At the 5’ end there is a cap 
consisting of guanine (G) nucleotides with a methyl group. At the 3’ end, the mRNA has a 
long link of several hundred adenine (A) nucleotides, commonly known as the poly(A) tail. 
The mRNA is transcribed by the RNAPII within the cell nucleus and the cap and tail 
modifications occur before the transcripts are exported to the cytoplasm, and they contribute 
in the identification of RNA molecules as mRNA. Both ends need to be present before protein 
synthesis can be initiated. [22]  
 
Figure 3: The segments of a mature mRNA consist of a guanine cap at the 5’ end, an 
untranslated region (UTR), a coding region for protein synthesis (the region varies 
depending on transcribed gene), a 3’ UTR and, finally, a poly(A) tail. The start and stop 
codons flag the starting and ending points for the translational machinery. [22] 
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2.3 mRNA regulation 
The mRNA-conversion from a pre-mRNA into a functional mRNA is an important step in 
gene expression. Traditionally, this process involves 5’ capping, intron splicing and 
polyadenylation at the 3’ end. [27, 28] But newer research has discovered novel co- and post-
transcriptional regulatory mechanisms, which also coordinate gene expression. 
Pre-mRNA to mature mRNA 
Capping is an mRNA modification which adds a guanosine cap. This process depends on 
three enzymes working in consecutive order: RNA triphosphatase, RNA guanylyltransferase 
and RNA-(guanine-7)methyltransferase. The cap functions by preventing degradation, while 
stimulating splicing and polyadenylation. [28, 29] Splicing alters transcription by removing 
introns and ligating exons in different patterns, allowing the same transcript to encode several 
different proteins. [29] Polyadenylation occurs when the RNAPII reaches the 3’ end of the 
coding region, this triggers a cleaving at the poly(A) site (AAUAAA) and leads to the 
addition of a poly(A) tail. [30] The poly(A) tail controls mRNA stability and translation by 
controlling the length of the of the 3’ UTR – the site for further mRNA regulation. [27] 
Co-transcriptional regulation 
RNA folding is an important for regulatory step and the folding can occur both co- and post-
transcriptionally. Continuing research and progress exists for this topic. Three (of many) co-
transcriptional steps, with the ability to incur co-transcriptional influence over RNA 
conformation, are listed below. 
 Transcription speed. The transcription of the 5’ end can take place up to several 
seconds prior to the 3’ region. This dictates the folding, as base coupling only occurs 
between previously synthesized RNA portions. [26] 
 Transcription pausing. Several factors dictate the nature of transcriptional pausing. A 
stop of the RNAPII can last a couple milliseconds up to seconds and influences RNA 
folding through the length of this pause. [26] 
 Co-transcriptional interactions. RNA binding proteins (RBPs) or RNA helicases 
interact with nascent RNA to prevent base pairing with the selected site or to facilitate 
interaction. [26] 
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Post-transcriptional regulation 
In post-transcriptional regulation of mature mRNA, it is mainly the UTRs targeted by trans-
factors – such as RNA-binding proteins (RBPs) or microRNAs (miRNAs) – which steer the 
regulatory events. [27] The UTRs make up the cis-elements which interact with cellular trans-
factors, together creating large, interacting macromolecules. [31] Examples of the activity of 
cis-acting and trans-acting factors are listed in table 1. 
Cis-acting elements Trans-acting elements 
 
Poly(A) binding protein (PABPC1): Is deposited 
on the poly(A) tail and participates in translation 
initiation and termination 
 
5’ UTRs: Contains regulatory elements such as 
IRES (Internal Ribosome Entry Site) and IRE 
(Iron Responsive Elements) involved in 
translation regulation. Also required for binding 
decapping enzymes for inducing mRNA 
degradation. 
 
CCR4-NOT4: Promotes transcription elongation 
and regulates mRNA decay.  
 
Coding sequence: Regions with many 
functions, for exmaple miRNA-binding sites and 
exon-exon junctions (EEJ), which guide splicing. 
 
Table 1: This table contains examples of cis- and trans-acting elements in mRNA regulation. [27] 
Although RBPs were previously considered the “primary mRNA regulators”, more recent 
studies have shifted this role to microRNA (miRNA). [31] The miRNA are among the most 
abundant regulatory genes in vertebrates. [3, 25] In humans, miRNA regulate more than 60 
percent of the protein-coding genes. [31] The miRNAs will be discussed in greater detail in 
the ‘Discussion’-section towards the end. 
2.4 mRNA quantification  
Cellular functions are expressed through varied levels and patterns of mRNA. The ability to 
quantitate mRNA concentration and to understand the transcription of individual genes has 
become exceedingly useful in many branches of molecular science, for example to study drug 
resistance markers in tumor cells, such as AREG in cisplatin resistant cells. [32]  
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The four methods commonly used for quantification of transcriptions are: 
 Northern blotting  
 In situ hybridization 
 RNase protection assays 
 Reverse transcription polymerase chain reaction (RT-PCR) 
 
Each method has its own strength, but the common limitation of the first three techniques is a 
relatively low sensitivity. The reverse transcription polymerase chain reaction is 
acknowledged as the most sensitive method. [32] Its great strength is its ability to amplify and 
analyze even the smallest amounts of DNA in cell samples. But due to the mRNA’s inherent 
instability, it must be reversed transcribed into complementary DNA (cDNA) by retrovirus’ 
reverse transcriptase, prior to PCR and DNA polymerase activity. [32, 33] 
2.5 Polymerase chain reaction 
Polymerase chain reaction (PCR) is a method for DNA amplification developed by Kary 
Mullis in the late 1980s. [34] With this method, any DNA template can be copied through 
repeated sessions of DNA replication. By adding the desired DNA primers, it will pair with 
the existing DNA strands and thereby guide the DNA polymerase to copy the following 
sections. [22] The amount of DNA molecules will increase exponentially as the replication 
proceeds, therefore, only a small amount of sample DNA is needed to create a much larger 
DNA pool. [34] 
The DNA primers are designed and synthesized oligonucleotides containing 15-20 bases of 
DNA. To start a PCR reaction, the operator must know the beginning and end sequence of 
their target DNA. [22] The primers provide the 3’ end for the DNA polymerase to start 
replicating and two primers will initiate a parallel occurring DNA synthesis, in opposite 
directions.  
The replication will begin by heating the template to a high temperature (e.g. 95 degrees), to 
separate the double-stranded DNA. Then the temperature is lowered, a sufficiently lowered 
temperature will allow the primers to bind and hybridize with their complementary sequences. 
A somewhat higher temperature will cause elongation, and then the process of heating, 
separating and extending will begin anew. [34] 
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PCR developed for the purpose of determining the amount of specific mRNA or DNA is often 
referred to as quantitative PCR or real-time PCR (qPCR).  
2.6 Real-time PCR 
When qPCR is used for mRNA quantification, the mRNA needs to be reverse transcribed 
(RT). The two methods, reverse transcription and qPCR, are often coupled together and the 
combination has become an important tool within gene expression analysis. [36] The joined 
practice is commonly known as reverse transcription quantitative polymerase chain reaction 
(RT-qPCR) or real-time reverse transcription PCR (real-time RT-PCR) and has become the 
“gold standard” for absolute and relative quantification of mRNA levels. [33, 37, 38] 
To accurately quantify cDNA, a reaction mix with primers and a fluorescent reporter dye is 
necessary. Through the entire amplification reaction, the dye will continuously bind to the 
PCR products. The computer registers the increase in fluorescent signal as the signal reaches 
the threshold for detectability. An automatic calculation estimates the sample’s original 
concentration. This is possible because the fluorescence is proportional to the amount of DNA 
product. [32, 39] 
 
Figure 4: From the beginning, the reaction mix contains both DNA and primers. In the first 
phase (denaturing), the reaction is heated to a temperature of 95
o
C. The dsDNA separates. 
This leaves two strands of ssDNA. The reaction is then cooled to ~50
o
C, entering its 
second phase (annealing). This temperature allows the primers to bind complementary 
ssDNA. In the third phase (extension), the reaction is reheated to 72
o
C and the primed 
ssDNA will replicate. With the end of replication, comes the end of the first cycle. The 
cycles are repeated many times, until the desired sample amount is achieved. [35] 
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Part 3: Materials and methods 
3.1 Experimental procedures 
3.1.1 Cell culture 
The two human OSCC cell lines PE/CA-PJ34 clone C12 (male, 60 years) from the oral cavity 
and PE/CA-PJ49 clone E10 (male, 55 years) established from tongue tissue, were cultured in 
standard medium (IMDM, Sigma-Aldrich, St. Louis, MO, USA), supplemented with 10% 
fetal bovine serum (FBS) (Cambrex, Verviers, Belgium), 2 mM L-glutamine, and 1% 
penicillin-streptomycin (PS) (Cambrex) at 37°C and 5% CO2. C12 is cisplatin sensitive, E10 
is cisplatin resistant.  
Cells were seeded at a density of 2 x 10
5
 cells per well in 12-well microtiter plates (nunc, 
Wiesbaden-Biebrich, Germany), that were at 80% confluency, in 2 µl IMEM with 10% FBS 
per well. Cells were harvested at 10 a.m, at time intervals of 15 minutes, 30 minutes or 2 
hours (specified in later in the text, for the individual experiments). The cell-culture medium 
was completely aspirated and washed twice by PBS, then added 350 µl Buffer RLT (RNeasy, 
Qiagen) in each well, pipetted a few seconds to get cells fully disrupted and afterwards 
transferred to 2 ml tubes and kept on ice. At this point, cell samples were ready for RNA 
isolation.  
3.1.2 mRNA isolation  
The cell precipitate was removed from the freezer upon mRNA extraction. Samples were 
stored at room temperature until liquid form. Under an RNase-free ventilated drain, the 
samples were added with 350 µl 70% ethanol. The entire content of 700 µl was then 
transferred to the RNeasy spin column (Qiagen) and centrifuged 1 minute (temperature 24°C, 
speed 130 rotations per minute). Each sample was first washed with 700 µl RW1 buffer, the 
precipitate was removed and the columns were centrifuged for 1 minute. Then we added 500 
µl RPE wash buffer, removed the precipitate and centrifuged for 1 minute. This process was 
repeated, and then centrifuged for 2 minutes. Afterwards, the top of the RNeasy spin tube was 
moved to a new 2 ml collection tube and re-centrifuged for 2 minutes. Precipitate was moved 
to a lidded 1,5 ml collection tube. Depending on the cell amount in the original samples, each 
tube was added with water (30-50 µl) and let rest for 1 minute, then centrifuged for 1 minute. 
The precipitates were moved to new tubes. 
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RNA samples are extremely susceptible to being destroyed by ribonucleases, so when 
working with RNA, gloves were used at all times. Due to low tolerance of high temperatures, 
the samples were kept in a freezer at minus 80
o
C and put on a cooling element when in use, 
according to recommendations. [40] 
3.1.3 Nucleic acid concentration 
Both the RNA quality and quantity needs to be assessed, without exact values it cannot be 
further utilized. Sample nucleic acid concentration was measured by the NanoDrop 2000c 
Spectrophotometer. The settings were adjusted for measuring RNA. The NanoDrop was then 
reset by calibrating the machinery to the contents of 1 µl RNase free water, set at “blank”, 
then cleaning the dispenser and adding the RNA samples. The nucleic acid concentrations 
were used to calculate the necessary µl sample needed to proceed with the reverse 
transcription, and each sample were also checked for their A260/A280-value, each ensured to 
be within the purity ratio of 1,8 and 2,2.  
3.1.4 Reverse transcription 
Reverse Transcriptase Core Kit (Eurogenetec) was utilized for the reverse transcription 
procedure. The instructions under “Procedure for Two step qRT-PCR reaction” were 
followed. The 10x reaction buffer, 25mM MgCl2, 2.5 mM dNTP and random nonamer were 
removed from the freezer and gently warmed at a temperature of 37°C, until the contents were 
liquefied. The reagents were added to a reaction vial (Eppendorf DNA LoBind Tube 1,5 ml) 
and mixed. Then, the RNAse inhibitor and EuroScript RT were added. The vial was put on 
ice, as RNA was added. RNA was calculated for total RNA concentration <200ng. The RT 
Reaction Mix was distributed into new tubes (Stratagene Optical Tube, 8x Strip) with the 
sample mRNA, then diluted with RNase free water, as needed, and finally lidded (with 
Agilent Technologies Optical Cap, 8x Strip). The finished sample was loaded into a preheated 
GeneAmp® PCR system 9700, for 45 minutes (10min at 25°C, 30min at 48°C, 5min at 95°C, 
then cooled down at 4°C until the operator manually terminates the program). The program 
settings were typed according to tube’s ml contents. The finished sample was stored in a 
freezer until the cDNA is needed. 
3.1.5 Quantification by real-time PCR 
Real-time PCR was performed using RealMasterMix with added SYBR Green (Eppendorf); 
1,0 ml of the 2,5x RealMasterMix added 125 µl of 20x SYBR Solution. The reaction mix was 
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calculated according to the manufacturer’s description. Forward primers and reverse primers 
(Sigma-Aldrich, Eurogentec) were added, for target gene and housekeeping gene (for exact 
sequences and manufacturer, see table 2). Sample cDNA was diluted with RNase free water, 
with a 1:3 ratio (sample:water). Trays of 96 wells were loaded with 8,4 µl reaction mix and 
6,6 µl sample cDNA. At least two parallel wells were loaded with sample and the normalizer, 
respectively. In each tray, the last two wells in sample and the normalizer group were added 
8,4 µl RNase free water, instead of reaction mix to ensure controls with no Ct-value. The 
completed tray is centrifuged with Megafuge 1,0R’s “quick run” function up to a speed of 
2000 rcf. The finished tray is then placed within the Mx3005P for quantification. Data was 
acquired through the MxPro QPCR Computer Software.  
 
Gene  Forward primer (Fw) Reverse primer (Rv) 
TBP TATA-box 
binding protein 
5’-CGTGGCTCTCTTATCCTCATGA-3’ 5’-GCCCGAAACGCCGAATATA-3’ 
HPRT1 Hypoxanthine 
phosphoribosyl-
transferase 1 
5’-TTGACACTGGCAAAACAATGC-3’ 5’-GCTTGCGACCTTGACCATCT-3’ 
AREG Amphiregulin 5’-GCTCAGGCCATTATGCTGCTG-3’ 5’-ACTCACAGGGGAAATCTCACTCC-3’ 
EGFR Epidermal 
Growth Factor 
Receptor 
5'-GTGGCATTTAGGGGTGACTC-3' 5'-CAGAATATCCAGTTCCTGTGGA-3' 
EGF Epidermal 
Growth Factor 
5’-GGTGGTGAAGTTGATCTAAAG-3’ 5’-TAGCATGTGTTGAGATTCTG-3’ 
Table 2: The primer sequences. , TBP, HRPT1, AREG, EGFR and EGF were purchased from 
the manufacturer Sigma-Aldrich. EGFR is from Eurogentec. 
There are many fluorescence-based technologies, in our lab we are experienced with using 
SYBR® Green, a fluorescent dsDNA binding dye. [38] When the PCR cycle amplifies the 
samples, the fluorescence will reach a threshold value of background fluorescence – this 
parameter is known as the threshold cycle (Ct) or crossing point (Cp). The larger the sample 
is at starting point, the lower the Ct-value. Based on the fluorescence and amplification 
product, calculations can be made for an accurate quantification of sample molecules. [39] 
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Figure 5: The amplification plot from qPCR (Mx3005P) as displayed in the MxPro QPCR 
Software. The blue line represents the threshold level; the lower limit for detection of the 
amplification products. When the graph crosses this mark, this results in a Ct-value or 
“threshold cycle”, which corresponds to the number on X-axis. The red ring marks the 
sample with the lowest Ct, this is the sample with the highest sample concentration (this 
corresponds to peaks at 1,5h in figure 11). (A) The cluster of lines represents the target 
gene. (B) Cluster of lines shows reference genes amplification pattern.    
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3.2 Methodological considerations 
3.2.1 RNA isolation 
RNA preparation and isolation methods may vary greatly. In this research, the RNA isolation 
method was a filter based or “spin basket” type. This uses a membrane - a silica membrane in 
the RNeasy spin column – which binds the desired product, while other organic contents pass 
through and become filtered out by centrifugation and then discarded. [41]  
Other extraction methods include: 
 Organic extraction: The chosen sample is combined with a solution which, after 
centrifugation, separates the sample in three phases. The first upper layer is the RNA. 
[41] 
 
Figure 6: The 96-well tray after a completed PCR as displayed in the MxPro QPCR Software. The 
blue numbers are the Ct-values of the added samples. Parallel wells (two or three which share the 
same number and letter, e.g. 1A) should not show values which diverge more than +/- 0,8 relative to 
each other. The average Ct-values of the parallel wells were used for the data presentation in part 4. 
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 Magnetic particles: By adding small, magnetic particles which target sample particles 
will make it possible to extract molecules of interest by using a magnetic field. [41] 
 Direct lysis: Simple extraction method, applied by adding a lysis buffer which 
stabilizes the nucleic acids. [41] 
All the methods have their pros and cons. Sadly, there is no established “standard” method for 
RNA isolation. The spin basket isolation method is regarded as an overall good method for 
RNA purification, but as it yielded a relatively low 260/230 purity number it may be 
indicative of choosing a spin basket technology other than Qiagen’s RNeasy kit for future 
research. Fortunately, this number has no impact on the qPCR results. On the other hand, 
sample 260/280 purity were within the desired range. An explanation of these values and their 
importance can be found below. 
3.2.2 Nucleic acid purity 
The assessment of nucleic acid purity preliminary to qPCR is important for reliable, final 
results. It is to control whether the purification of sample contaminants is adequate, and the 
evaluation is completed by studying the 260/280 and 260/230 ratio of sample RNA. These 
numbers were established with the NanoDrop spectrophotometer, a device which measures 
the absorption of light with wavelengths 230, 260 and 280 nanometers (nm). Products which 
absorb the different wavelengths: 
 280nm - absorption of proteins (specifically aromatic amino acids) [42] 
 260nm - absorption of nucleic acids (DNA & RNA) [42] 
 230nm - absorption of organic contaminants and solvents [42] 
All nucleotides, RNA, ssDNA (single-stranded DNA) and dsDNA (double-stranded DNA) 
will absorb waves at the 260 nm wavelength and increase the total absorbance of the sample. 
[43] In summary, the NanoDrop assesses both the quantity of the RNA (nucleic acid 
concentration in ng/µl) and the quality. The quality is described by the two aforementioned 
ratios, the separate numbers convey the following information: 
 260/280 
The RNA quality is determined by analysis of the 260/280 ratio, a number which expresses 
the sample’s purity; its absence of proteins, DNA contamination and inhibitors. [39] A ratio 
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of approximately 2,0 is generally accepted as pure RNA. As the ratio decreases, the purity 
also decreases, because the protein contamination rises. [42] In our selection, the samples 
have abided by the recommendation of a 260/280 ratio ~2, samples with a maximum 
deviation of 0,2 in a positive or negative direction (+/- 0,2) were included in the experiments.   
 260/230 
Secondary to the 260/280 ratio, there is the 260/230 ratio. Values for the 260/230 ratio are 
expected to fall within the range of 2,0-2,2. If the ratio is lower, this indicates that there may 
be contaminants that absorb wavelengths at 230 nm. [44] The 260/230 ratio has had no value 
in the selection or disposal of samples, as this specific ratio is insignificant in RT-qPCR. 
3.2.3 RT primers 
When choosing primers for the reverse transcription and cDNA synthesis, it has been debated 
whether random nonamers or poly-dT would serve as the best primer. It is implied that, as the 
poly-dT primer begins by binding samples at the complementary poly(A) tail and needs to 
transcribe the mRNA’s entire length, a poly-dT primer will result in a lesser but more 
accurate amount of cDNA product, when compared to transcription by random nonamers. 
This is additionally explained by speculating that random nonamers will bind randomly to all 
the RNA and facilitate transcription of both the desired RNA product, as well as the partially 
degraded RNA. [45] Because of this ambiguity, experiments with the use of poly-dT and 
random nonamer primers were conducted. No obvious discrepancy was observed by the two 
parallel methods.  
3.2.4 Quantification method 
As previously established, qPCR is a great and common choice for quantification of DNA and 
RNA. Nevertheless, there are certain elements in the procedures from the RNA extraction to 
the completed PCR which can create variations and instabilities in the results. [47] There are 
two ways for DNA quantification in RT-qPCR – absolute and relative quantification. We 
have used the latter, as it is widely used and sufficient for our purpose as explained by 
Michael W. Pfaffl: 
“Relative quantification is easier to perform than absolute quantification [...]. 
It is based on the expression levels of a target gene versus a housekeeping gene 
(reference gene or control gene) and in theory is adequate for most purposes 
to investigate physiological changes in gene expression levels.” [46] 
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This type of data normalization relies on a good and stable reference gene for correct results. 
[48]  
3.2.5 Housekeeping genes for qPCR data normalization 
The use of housekeeping genes (HKGs), or endogenous reference genes, is widely regarded as 
a suitable method for data normalization in RT-qPCR. The HKGs are endogenous as they 
already exist in the sample and function in the coding of the most fundamental cellular 
activities and processes. HKGs are necessary for the homeostasis of the cell and should 
normally be expressed at constant levels. [47, 49] By comparing the Ct of the target gene 
sample with the Ct of the HKG, the gene expression can be normalized. [50] 
Although these genes are assumed to be relatively stable, there is increasing evidence that 
many of the HKGs are not as resistant to environmental changes as it was previously thought. 
[47] A review by Bär et al. points out that different types of HKGs were appropriate for the 
study of adult keratinocytes, while not every one were appropriate for studying juvenile 
keratinocytes. [51] In another review, by Jacob et al., it was noted that GADPH was among 
the least stably expressed reference genes, despite being the most frequently used, as different 
disease stages could alter its gene expression. [38] 
To optimize the normalization, the reference genes should embody certain qualities: 
 Expression at constant levels in different tissues. [33] 
 Consistency through all environmental and experimental conditions. [47] 
 Expression at similar levels as the studied RNA. [33] 
 Should undergo all steps of the reaction with the same kinetics as the target gene. 
[33] 
 
Accurate normalization of gene expression is an absolute prerequisite for precise 
quantification of target nucleic acid, which is why the study of HKG-reliability is such an 
important part of qPCR. In a study by Radonić et al., RT-qPCR was used to measure mRNA 
of 13 HKGs in 16 different human tissues, with the aim of determining which were the most 
stable. [52]  
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The results among the 13 HKGs were varying. None of the HKGs showed stable expression 
levels in all the tissue samples; each expression level shifted from one tissue to another, but 
some samples showed a much greater variation.  
To estimate the extent of diversity, the range between lowest transcription level (high Ct) and 
highest transcription level (low Ct), was depicted in percentiles. The gene with the lowest 
range should suggest a relatively constant transcription level in the 16 tissue samples and 
therefore trustworthy. [52] 
 
Figure 7: The RNA transcription levels of 13 HKGs in different tissue 
samples, showing how the levels vary in different tissues. Some samples 
show greater tissue variations than others. Ct ≥ 45 is not depicted. [52] 
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The results argue that TBP is most stably expressed HKGs among the chosen 13, while HPRT 
is among the least stable. A publication by Minner and Poumay also suggest the use of TBP, 
but preferably together with two other HKGs. [53] 
In the results, which will be presented shortly, we have followed the recommendation of using 
multiple HKGs to minimize errors. [52, 54] The two reference genes used for qPCR were 
TBP and HPRT, chosen primarily due to availability. This should be taken into consideration 
if the experiments were to be repeated, as there could be HKGs better suited for the study of 
OSCC, than the two in our selection. 
 
Figure 8: The ranges between lowest and highest Ct-values are depicted. Grey 
boxes mark the 50% percentile, with a black line within representing the median. 
Vertical whiskers indicate the 80% percentiles. Dots are outlying results. TBP, RPII 
and Tub showed the lowest ranges, and are therefore assumed to be the most 
stable. On the opposite end of the spectrum; Alb, HPRT and PBGD displayed the 
largest ranges. [52] 
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3.3 Experimental background  
During the introduction it was already mentioned how the very first experiment relating to 
mRNA fluctuations was actually executed by one of my supervisors, Ph.D-candidate Jian 
Gao. This experiment studied cell samples which were handled and harvested with 2 hour 
intervals. The PCR results showed fluctuations in the amphiregulin-levels. This sparked 
interest but it also inspired questions. 
 
 Are the fluctuations cyclic occurrences or random peaks?  
 Are the 2 hour intervals depicting an accurate rendition of the mRNA cycles? 
 Is the experiment repeatable?  
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Part 4: Results 
4.1 Data presentation 
My work has primarily involved mRNA extraction, 
reverse transcription and quantitative PCR runs. Different 
cell samples have been studied and each sample was 
subjected to several reverse transcriptions and PCR runs. 
The charts which will be presented in this thesis are 
chosen from PCR results which best represent the many 
trials – a sort of “median” of each sample. The total 
number of completed PCR runs is summarized in table 3. 
The composition of experiments – choice of primers and 
housekeeping genes – were decided in a dynamic manner, 
meaning that as the work was conducted, questions arose 
and this became the guide for choosing these variables. 
The original intent was to study the amphiregulin 
fluctuations – to verify or deny the existence of periodical 
peaks.  
 
Each experiment studied cells harvested with a defined 
interval in time, throughout a defined period of time. 
Then the Ct-values of the HKG are subtracted from Ct 
of sample gene, producing in the ∆Ctvalue. The ∆Ct of 
the first sample (defined as the ‘calibrator’ or 0h) is 
subtracted from the ∆Ct of another sample, e.g 0,5h, 
and results in the value ∆∆Ct. The negative value,  
-∆∆Ct, is added as an exponent of 2. The resulting 
number marks a coordinate in a graph. Calculations are 
summarized in figure 9. The 2
-∆∆Ct
 method is used, as 
recommended by Jensen, for creating the data presented 
in the following plots and charts [33], unless other values 
are specified. 
Total number of PCR runs = 18 
Divided by sample gene primer: 
AREG 12 
EGFR 1 
EGF 2 
HRPT 3 
Divided by RT-primer 
RN 16 
Poly-dT 2 
Divided by HKGs: 
TBP 14 
HRPT 4 
 
 
Table 3: All the 18 PCR runs, 
subdivided by the use of DNA primer, 
reverse transcription primer and HKGs. 
 
Ct target gene - Ct normalizer = ∆Ct 
∆Ct samples - ∆Ct-calibrator = ∆∆Ct 
Time fold = 2
-∆∆Ct  
      
 
 
Figure 9: The calculations for the values 
in our line chart are calculated through 
the 2
-∆∆
Ct-method. [33] Target gene is 
normalized to reference gene. Resulting 
number is normalized to the calibrator (0h 
sample normalized to 0h reference gene). 
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4.2 Selection of time intervals 
The first experiment, conducted by myself in cooperation with Jian Gao, used the cell line 
(cisplatin resistant E10) and primers (AREG and TBP) from the original experiment. The 
cells were harvested at 0,5 hour intervals through a 4 hour period, then harvested again at 6 
hours and lastly at 8 hours.  
 
Figure 10: Peaks are observed at 1,5h and 2,5h, but the large intervals between the 
4h, 6h and 8h time points exclude any possibility of predicting a pattern in the two 
areas 4h to 6h and 6h to 8h (marked with orange ‘?’), therefore leaving two empty 
gaps.  
 
In figure 10, two peaks can be visualized at the 1,5h and 2,5h (1,5 hour and 2,5 hour) time 
points, but due to the 30 minute interval between each interval, it is unlikely that the chart 
displays the precise moments when the graph peaks, as the 1,5h and 2,5h points could be 
somewhere along the function’s increase or decrease. What is even more uncertain is the 
graph’s course past the 4h time point, as the 6h and 8h values alone add minimal or no 
additional information. 
 
Due to these uncertainties, it was established that the intervals between cell harvesting should 
be as narrow as possible and happen as tightly as human execution would allow. The fixed 
intervals for all the following experiments were therefore set at 15 minutes – the shortest span 
that could practically be achieved. 
4.3 Selection of reverse transcription (RT) primers 
As previously discussed, the execution of reverse transcription comes with the dilemma of 
primers. In the reverse transcription kit, both random nonamers (RN) and poly-dT are 
26 
 
delivered as available choices. Our lab at the Department of Oral Biology, uses RN as the 
preferred method. However, because the RN primers may transcribe even fragmented 
denaturized RNA and clutter the results, we ran a parallel RT with both RN and poly-dT. 
 
Two RTs were completed with poly-dT as primer (see table 3). The results yielded two 
graphs with striking pattern heterogeneity. The first fluctuated wildly, while the second 
showed peak timings resembling that of the RN graphs.  
Figure 11: Parallel reverse transcription of one sample with poly-dT and 
random nonamers; resulting graphs showed parallelism in fluctuation. Both 
are AREG normalized  to TBP. 
 
The above graph displays a comparison between the second poly-dT AREG/TBP-graph and a 
typical AREG/TBP-graph reverse transcribed with RN. No considerable divergences could be 
noted, as the two graphs displayed quite a lot of similarity in fluctuation.  
Because the uncertainty regarding the results yielded by poly-dT, it was considered a less 
stable primer and we resolved to conduct future RTs with RN, which had showed consistency 
throughout the different experiments. 
4.3 Amphiregulin (in E10) 
The first four results from the PCRs showed some discrepancy, the charts showed quite 
contradictive amounts – a few were alike, while others shared no pattern whatsoever. These 
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can be subtracted from the 18 total PCRs, due to the operator being in training. The later 
results were more stable and are well represented by steadily showing peaks at time points 
1,5h and 3h (fig.12). The more consistent results were selected for the data presentation and 
comparison in later segments. 
4.4 EGFR and EGF (in E10) 
The possibility of mRNA fluctuation in AREG was well established when it was decided to 
compare the results with other genes. From a list of primers, two were selected – EGFR and 
EGF. The first is a transmembrane receptor in the ErbB-receptor family, while the latter is a 
ligand. The samples were reversed transcribed with RN in the same, parallel process, but in 
separate PCRs. 
 
EGFR EGF AREG 
0h 1 1 1 
15min 0,87 0,962 0,491 
30min 1,04 0,669 0,809 
45min 0,911 0,772 0,523 
1h 0,859 1,17 0,681 
1h 15min 0,875 0,75 0,526 
1h 30min 1,26 4,39 1,77 
1h 45min 0,967 1,34 0,771 
2h 1,37 0,892 0,768 
2h 15min 1,44 1,18 0,678 
2h 30min 1,31 0,941 0,72 
2h 45min 1,36 1,24 0,78 
3h 1,62 1,72 1,11 
3h 15min 1,14 2,19 0,877 
3h 30min 1,11 1,25 0,536 
3h 45min 1,07 0,662 0,52 
4h 1,11 0,911 0,566 
 
Table 4: Table containing values, obtained through the 2
-∆∆
Ct-method as described in figure 9. 
Numbers are used as coordinates for figures 12–16 and will not be repeated in ensuing charts 
or texts. 
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4.4.1 Epidermal Growth Factor Receptor (EGFR) 
 
 
Figure 12: EGFR showed surprisingly little fluctuation and seemed relatively 
stable. Although one can register a few peaks, the comparatively most 
prominent peak is at the 3h time point. 
 
 
 
 
 
 
 
 
 
 
Figure 13: EGFR compared to AREG. Both graphs have coinciding peaks at 
the 1h 30min and 3h time points. But EGFR shows a relatively more stable 
increase, making the peaks less prominent, while AREG is better 
characterized by “spikes”. 
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EGFR alone shows no prominent “spiky” pattern (figure 12). When EGFR is compared to 
AREG (figure 13), the overlapping patterns show peaks at 1,5h and 3h time points, but the 
AREG peaks are clearly much better defined. When observing this difference, it inspires 
speculation; could this dissimilarity be caused by the two products’ contrasting purposes? As 
EGFR is a membrane-bound receptor, perhaps a lesser turnover – when compared to AREG 
which is a ligand – is reflected in its relatively stable mRNA expression over time.  
4.4.2 Epidermal Growth Factor (EGF) 
 
Figure 14: EGF fluctuation, peaks at 1h 30min and 3h 15min. 
 
 
 
 
 
 
 
 
 
Figure 15: EGF compared to AREG. The first peaks coincide at the 1h 30min.  
But EGF’s second peak is slightly delayed when compared to AREG. 
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Figure 16: EGF compared to EGFR. The large fluctuations in EGF makes the 
EGFR seem relatively stable, in comparison. 
 
At first glance the EGF-chart looks a lot more similar to the previous AREG results (figure 
14). But the first peak is quite large, as it represents an almost 4,5-fold increase in the mRNA 
compared to the starting 0h calibrator, it trumps AREG’s measly 1,8 fold peak (figure 15). 
When EGF is plotted together with EGFR (figure 16), their difference in quantity becomes 
even more evident, supporting the theory that ligands and receptors may have a different 
expression of mRNA fluctuation – thereby also suggesting that mRNA fluctuation is an 
expression of some inherent biological system. 
4.5 Control of the housekeeping genes (HKGs) 
Upon examining the results, it became almost definitive that mRNA fluctuations did exist. 
But even if we ascertained its existence, it was still necessary to locate the fluctuations’ 
origin. The three most probable sources are listed below: 
 The target gene 
 The reference gene (HKG) 
 A combination of the target gene and reference gene 
 
To examine this, it was decided to better examine the reference genes. A new HKG was 
introduced to the experiments and the purpose was to study two HKGs instead of one. As 
previously established, HKGs are recognized and used for their relative stability in different 
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tissues and through longer periods of time. The chosen experiment was therefore based on the 
assumption that a PCR with one HKG as target gene and the other HKG as reference gene 
should result in a graph displaying less fluctuation than the ones we have previously studied. 
The hypothesis was based on the belief that HKGs were stably expressed over time, therefore, 
cyclic fluctuations should be caused by genes other than recognized HKGs. And if this was 
not the case, perhaps even HKGs increased and decreased periodically. 
 
Figure 17: Graph with HRPT as target gene and TBP as reference gene. Results 
indicate how HKGs also fluctuate in a cyclic manner when studied over time. The 
peaks occur at time points 1h 30min and 3h – same as the previously shown AREG-
fluctuations. 
The results from the normalization of HPRT to TBP (figure 17) show two peaks occurring at 
1h 30min and 3h; this is the same two time points as the peaks in the AREG-function 
occurred. HKGs show periodic fluctuations and this complicates our data analysis, as one 
cannot exclude the HKGs as a potential source for cyclic mRNA variations. Whether it is the 
target genes or HKGs which are causing the changing graphs is impossible to know at this 
point, but neither can be excluded. 
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Figure 18: AREG calibrated to HRPT shows no significant difference from AREG 
was calibrated to TBP. First peak is at 1h 30min and second peak at 3h. 
 
When TBP was excluded and AREG was normalized to HPRT (figure 18), the fluctuations’ 
peaks appeared consistently at 1,5h and 3h. It seemed that cyclic variations were unavoidable. 
Results from the three previous experiments (AREG to TBP, AREG to HPRT and HPRT to 
TBP) showed the same two peaks occurring at the same two time points, it makes us wonder: 
Which gene is actually causing the fluctuations, is it one, two or all three? Or is it none, but 
simply an experimental error? 
To better understand HKG-variation, the Ct-values for the two HKGs through a four-hour 
period are displayed in figure 19. Each graph represents one PCR, so every function is 
singular and separate from the rest. Figure 19 is different from previous results as resulting 
numbers have not been normalized nor calibrated. The unprocessed HKG-figures (table 5) are 
not strikingly aberrant and it is unlikely that fluctuations from the previous plots could be 
initiated by the HKGs alone. 
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Table 5: Table containing Ct-values of the samples presented in figure 19. 
 
Figure 19: Ct-values of HRPT and TBP, respectively, from different PCRs. The 
numbers represents the dates when the PCRs were completed (year 2013). 
 
HPRT from 
TBP-HPRT 
19.8 
HPRT from 
AREG-
HPRT 19.7 
HPRT from 
AREG-HPRT 
22.7 
TBP from 
TBP-HPRT 
19.8 
TBP from 
TBP-HPRT 
19.8 
TBP from 
AREG-
TBP 29.7 
TBP from 
EGF-TBP 
27.7 
TBP from 
EGFR-
TBP 24.7 
0h 24,81 21,16 21,95 27,82 27,82 29,68 28,29 27,81 
15min 26,79 20,73 20,64 29,02 29,02 29,65 28,74 28,14 
30min 26,32 20,96 21,47 28,48 28,48 29,88 29,18 28,32 
45min 26,84 20,27 21,61 28,87 28,87 29,84 28,85 28,37 
1h 26,61 20,3 21,88 28,94 28,94 29,96 29,04 28,22 
1h 15min 26,26 19,58 21,65 28,49 28,49 28,81 27,99 27,83 
1h 30min 25,45 20,52 21,4 29,7 29,7 29,8 29,91 28,74 
1h 45min 26,74 19,77 21,23 29,58 29,58 29,6 29,58 28,5 
2h 27,01 18,92 21,45 29,66 29,66 29,86 29,24 28,82 
2h 15min 27,06 20,07 21,21 29,59 29,59 30,14 29,01 28,88 
2h 30min 26,81 19,07 21,27 29,35 29,35 30,1 29,14 28,97 
2h 45min 27,56 20,05 20,99 30,05 30,05 30,41 29,48 29,39 
3h 27,05 19,83 21,83 30,46 30,46 29,45 29,28 29,16 
3h 15min 27,6 19,48 21,4 29,67 29,67 30,48 29,91 29,35 
3h 30min 28,27 19,72 21,15 30,27 30,27 30,18 29,37 29,26 
3h 45min 28,66 18,94 20,89 30,95 30,95 30,71 29,5 29,17 
4h 28,42 19,19 21,25 29,86 29,86 29,72 29,64 28,96 
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4.6 Comparing to cell line C12 
Up to this point, the results have indicated the 
presence of fluctuations in different genes, but 
all cells were cultured from one cell line – 
E10. To examine whether mRNA fluctuations 
were a general biological phenomenon, the 
PCRs were repeated in the cisplatin sensitive 
cell line C12. The experiments were 
completed towards the project’s end, which is 
the reason for not including more repetitions 
to ensure greater accuracy.  
To extend the study, the total time length for 
cell extraction was prolonged by one hour, 
from 4 hours to 5 hours. AREG and EGF were 
selected as target genes and both were 
normalized to TBP. For listed details and 
accurate numbers, see table 6. 
The acquired results for cell line C12 are 
shown in figure 20. In figure 21-22, AREG 
and EGF from C12 are analyzed with 
matching experiments from cell line E10. 
Results representing E10 have been shown in 
previous sections and to ensure the most 
accurate comparison, parallels share both 
target gene primers and reference genes 
primers.  
By comparing the graphs, it is quite simple to 
notice dissimilarity in the graphs’ development. A possible explanation for this may be 
technical inaccuracies, but the graphs’ irregularity is still noteworthy. Nevertheless, the 
inherent fluctuations can be recognized in both genes.   
 AREG EGF 
0h 1 1 
15min 1,15 1,11 
30min 0,726 0,785 
45min 0,949 1,18 
1h 1,56 2,86 
1h 15min 1,64 1,14 
1h 30min 1,26 1,16 
1h 45min 2,05 0,455 
2h 1,12 0,114 
2h 15min 0,785 0,164 
2h 30min 0,677 0,215 
2h 45min 0,687 0,291 
3h 0,875 0,166 
3h 15min 1,08 0,118 
3h 30min 2,06 0,97 
3h 45min 1,86 4,41 
4h 0,778 0,144 
4h 15min 0,476 0,131 
4h 30min 0,607 0,183 
4h 45min 0,614 0,355 
5h 1,21 0,191 
 
Table 6: Table containing values, obtained 
through the 2
-∆∆
Ct-method as described in 
figure 9. Numbers are used as coordinates for 
figures 20-22 and will not be repeated in later 
segments.  
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Figure 20: Graph illustrating normalized Ct-values for AREG and EGF, acquired 
from cell line C12. Both are normalized to TBP. The exact values are listed in table 
6. The highest peaks for AREG are found at 1h 45min and 3h 30min. The highest 
peaks for EGF occur at 1h and 3h 45min. The graph patterns develop in a similar 
manner with peaks and dips. There is a noticeable dissimilarity of pattern 
progression as the peaks occur at greatly varying heights and at different time 
points.  
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Figure 21: Comparison of AREG from the two different cell line (E10 and C12) 
shows great disparity of the patterns. Details for AREG from E10 can be found in 
table 4. The graph is also depicted in figure 13.  
 
Figure 22: Comparison of EGF from the two different cell line (E10 and C12) shows 
great disparity of the patterns. Details for EGF can be found in table 4. The graph is 
depicted in figure 14-15.  
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4.7 Summarizing the results 
The results above show how the fluctuating patterns differ between the different genes and 
also between the two cell lines. In all the presented graphs, there is an unmistakable 
individuality in each graph and its pattern course. The fluctuations indicate the changes in 
each gene’s mRNA concentration and, by extension, that gene’s expression. By examining 
these results, it seems that mRNA expression varies in a cyclic manner. If this is the case, the 
study and understanding of mRNA regulation becomes extremely complicated. However, this 
indication is only a hypothesis and the hypothesis is only tentative. We cannot exclude the 
possibility that the mRNA fluctuations are stochastic events. Our results are only suggestive 
and are by no means definitive. Before any conclusion can be reached, the complex nature of 
mRNA needs to be better understood and further research is still needed. 
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Part 5: Discussion 
5.1 Oscillations in literature  
Many researchers have published and discussed the fluctuations of mRNA but the topic has 
received surprisingly little attention. While most remain unaware of this observation, studies 
which discuss this matter have already coined it with the term “mRNA oscillations”. Many 
methods for protein quantification and mRNA analysis exist and different techniques are used 
by various researchers. While many agree with the existence of mRNA oscillations, some also 
suggest that similar oscillations take place in protein expression – thereby further confirming 
its relevance for gene expression. 
Whereas we used RT real time quantitative PCR to study mRNA fluctuations, others have 
used different methods and observed similar developments. [55] In a study by Geva-Zatorsky 
et al. [56], individual cells were studied by time-lapse fluorescence microscopy movies. They 
captured images of the cells’ fluorescence every 10-20 minutes and discovered fluctuating 
protein levels in different cells – some changes resembled oscillations, while others did not. 
The authors observed that DNA damage was followed by oscillatory behavior in the p53 and 
Mdm2 protein systems, and that the fraction of oscillating cells increased with an increasing 
dosage of gamma irradiation – an observation confirmed by others. [56] Lev-Bar Or et al. 
discovered an oscillatory response in various cell types to ionizing radiation and suggested 
that oscillations were a response to a stress signal and allowed for damaged DNA to be 
repaired. [57] On the other hand, in a single-cell experiment by Hat et al., the p53 (and NF-
ĸB) system displayed oscillations which were insensitive to the strength of stimulation. [58] 
The above examples illustrate how inconclusive the studies regarding oscillatory gene 
expression are, although several sources agree that such fluctuating behavior exists for both 
mRNA and protein. Both stochastic and cyclic behaviors may produce oscillating mRNA 
levels and protein expressions, yet there is still no conclusive explanation for the mechanisms 
regarding oscillations; their initiation, regulation or their effects on cellular protein 
concentration and gene expression. [55, 59] 
5.2 Gene fluctuations – stochastic or cyclic? 
Variation in mRNA concentration has been described as both stochastic fluctuations and 
temporal oscillations. [55, 59] The stochastic variations have been described by Rodríguez et 
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al. They discovered random fluctuations in the mRNA, which were amplified during 
translation and generated sustained pulses of protein expression. [59]  Whereas Tiana et al. 
described temporal or cyclic oscillations, where oscillations reoccurred after a certain period 
of time. The temporal oscillations were further subdivided as ultradian oscillations – which 
were observed with a few hours’ time interval – and circadian oscillations which echoed with 
24 hour rhythms. [55]  
Most authors regard these mRNA-protein fluctuations to be part of a negative or positive 
feedback loop system. [55, 59]  
5.3 Possible mechanisms 
Feedback mechanisms 
Negative and positive feedback mechanisms are common in cellular systems. It exists by 
having one variable which either activates or represses its preceding variable – this creates a 
positive or negative feedback mechanism, respectively. [55] The reason why the negative 
feedback loop is such a widely renowned explanation for oscillations, is because oscillatory 
behavior is described in many aspects of biology and biological systems are frequently 
regulated by this type of negative feedback mechanism. Examples of such regulation can be 
found in nerve signals and circadian clocks. [60]  
Others, on the other hand, believe the oscillations are due to a positive feedback mechanism. 
Lev Bar-Or et al. have observed fluctuations in relation to stress signals in the p53-system. 
These authors suggested that the pulses in protein expression are initiated and sustained by 
damage; that the spikes are continuously sent until damage is repaired. If the damage is 
extreme, the amplitude and duration of the pulse will induce p53-overexpression, and thereby 
apoptosis. [57] Geva-Zatorsky et al. also observed that the amount of oscillating cells 
increased along with an increase in gamma irradiation dose, yet this could not fully explain 
the variability:  
“Deterministic simulations cannot capture the variability in the oscillation 
amplitudes observed in the cells. We therefore added internal stochasticity to the 
equations.” (Geva-Zatorsky et al.) [56] 
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Noise and stochasticity 
Some cells studied by Geva-Zatorsky et al. did not express oscillatory fluctuations; instead 
they displayed slow, varying fluctuations. [56] Rodríguez Martínez et al. have proposed 
several models for such fluctuations, but find them insufficient. Instead, they support the idea 
of a noise element during protein production which creates the variability in oscillations, 
meaning that they accept the presence of stochasticity in their theory. They have developed a 
fully stochastic model in mRNA expression, described and tested through mathematical 
models, and propose that the fluctuations may be inhibited by regulatory RNA (regRNA), 
such as microRNA. [59] 
Despite the ongoing debate regarding the mechanism of these oscillations, many authors [61] 
agree that: 
“[…]oscillations in protein concentrations or gene expression levels are related to 
the presence of at least one negative feedback loop in the regulatory network.” 
(Pigolotti et al.) [62] 
Pigolotti et al. pronounce oscillations as a physiological process; an idea which disagrees with 
the abovementioned “response to DNA damage”. [62] This discrimination affirms our 
observation, because the oscillations in our results occurred without provocation by any 
external stimuli. Our interpretation of the foregoing data strongly concurs with the hypothesis 
that a feedback mechanism is the key source for fluctuations in the mRNA.  
Any mRNA regulatory mechanism could be capable of gene expression modification but, as 
suggested previously, a likely suspect is the previously mentioned regRNA and particularly 
the microRNA regulatory system. 
5.4 microRNA  
microRNA (miRNA) has a great impact on the transcription of mRNA and a very likely 
regulatory mechanism –  a possibility authors researching the field of mRNA fluctuations are 
becoming  increasingly aware of. Due to the miRNA’s diverse ability to participate in 
feedback and feed-forward mechanisms, it is viewed as the next target in the study of gene 
oscillatory behavior. [59]  
miRNAs are short non-coding RNAs, ranging from 20 to 24 nucleotides in length. They have 
important gene regulatory functions and can modulate both mRNA stability and translation. 
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[63] By Treiber et al., the mRNAs are referred to as “key regulators of literally all cellular 
pathways”. [64] The miRNAs participate in gene regulation and can induce either down-
regulation or up-regulation of translation. [65] 
5.4.1 Down-regulation 
The repressing acts of miRNA are primarily through repression of mRNA translation or 
degradation. The process is complex and the exact mechanics regarding how miRNA chooses 
their target genes are still unknown. [65] Several pathways for repression has been described, 
but in general terms, the inhibition of protein synthesis through miRNA is either by repressing 
translation or by deadenylation and destabilization of mRNA target. [66, 67] They have many 
different functions: 
 Repression of translation initiation. 3’ UTRs can be targeted by miRNA, causing 
repressed initiation of translation, by preventing ribosomal loading of mRNA. [66, 68] 
 Post-initiation repression. miRNA initiated repression can occur during translation, 
either as the polypeptide chain is made or after its completion. miRNA initiates decay 
of newly synthesized polypeptide chain. Whether the process is post- or co-
translational is under discussion. [65, 67] 
 mRNA decay. miRNA associated with proteins in the AGO/eIF2C family can form 
miRNA-induced silencing complex (miRISC). miRNA guides these complexes to 
mRNA. A partially complementary base pairing leads to sequence-specific repression 
or mRNA degradation. [63-65] 
 5’ cap. Some translation is cap-dependent; to initiate translation, the recruitment of 
initiation factors at the 5’ cap is necessary. miRNA may interfere with the recruitment 
or function of these factors. [66] 
 Storage or degradation. miRNA association with P-bodies and Stress Granules (SGs) 
seem to induce silencing of mRNA by preventing targets from reaching the ribosomes 
for translation. The silencing is either through degradation or storage. [65] 
5.4.2 Up-regulation 
Activation or up-regulation of mRNA translation through miRNA is a new discovery, but it is 
only reported under special conditions, like during the cell cycles G0/G1. Repression has also 
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been observed in G1-phase, so a more generalized premise for up-regulation is not yet 
discovered. [66, 68] 
5.4.3 miRNA – reflected in mRNA? 
The very first miRNA was identified approximately 20 years ago. Today, about 900 miRNAs 
have been identified. [69] miRNA is recognized for its wide range of regulatory functions, 
and its importance in cellular mechanisms is becoming increasingly clear. miRNAs are 
identified as both tumor suppressors and oncogenes; their role and participation in 
oncogenesis is therefore a subject of widespread interest. [70] 
To summarize, although the connection between mRNA fluctuations and miRNA is not yet 
evident, the mere possibility of a connection inspires important questions. The first question 
which needs to be answered is whether miRNA is the regulatory mechanism that creates the 
mRNA peaks. The second question, which perhaps is even more important, is whether 
fluctuations in mRNA can be mirrored by fluctuations in miRNA. Both points are essential to 
understand how mRNA oscillations are regulated. Research in this field is undoubtedly 
needed. 
5.5 Implications of the results 
The oscillations in the mRNA resulted in greatly varying patterns. Dips and peaks were noted 
for every single result, but the time point for an occurring peak and its peak height showed 
remarkable inconsistency. The most noteworthy result showed an amplitude which expressed 
an mRNA-level seven times greater than the 0h calibrator, expressing how the extent of 
mRNA fluctuation truly can be extreme. 
To illustrate the implications of the collected data, figure 23 shows EGF’s pattern through a 
4h time period. Horizontal line marks the threshold as the samples reach a concentration that 
shows a 50 percent increase in comparison to baseline, in other words, the concentrations are 
at least 1,5 times the 0h value (1,5 x 0h). These areas are marked with yellow and apply for 
intervals 1h 15min to 1h 45min and 3h to 3h 30min, this amount to a total time period of ~30 
minutes for the first yellow area and 30 minutes for the second area. The total amount of time 
in which the mRNA increases from 1,5 to 4,5 times the original baseline concentration 
becomes approximately 1 hour – ¼ of the total 4 hour time period.  
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Figure 23: The fluctuation of EGF over a 4 hour period results in two prominent 
peaks. The threshold value, the horizontal black line, is set at 1,5 x the 0h baseline 
concentration, meaning that graph areas which cross this threshold, display an 
mRNA-concentration which is equal to or higher) than the original value of mRNA. 
Graph areas which is ≥ 1,5  x 0h baseline, in comparison to 0h baseline, is marked 
in yellow. Times which correspond to these concentrations are the ranges 1h 
18min to 1h 45min and 3h to 3h 30min.  
Under most conditions, mRNA quantification with RT-qPCR is executed at a single time 
point. By using the data above to illustrate, one sample could show a concentration from any 
time point between 0h and 4h, in the above graph. It could have a concentration similar to the 
30min time point (0,75 x 0h value) or the 1h 30min time point (4,5 x 0h value). Regardless of 
the resulting number, it would be assumed to be the “truth”. But except for the two peaks 
(yellow area in figure 23), the rest of the graph stays relatively stable, ranging from 0,5 to 1,5.  
In conclusion, ¾ of the samples represent stability, while ¼ show aberrant fluctuations. When 
a specific mRNA sample is quantified and the value from that specific time point is used, that 
number is regarded as a mean level of mRNA concentration. The mRNA levels are assumed 
to be stable over time, but this data clearly contradicts this. It proves how mRNA levels for a 
gene cannot be based on one single measurement. Two different genes cannot be compared by 
two separate mRNA quantifications – one measurement may be a “peak” value and the other 
may be a “bottom” value. The total mRNA production for a target gene is expressed by the 
area under the graph because the levels are not stable, they fluctuate over time. 
44 
 
5.6 Correlation between mRNA and protein 
The variation in mRNA levels may explain the discrepancy in translating mRNA values to 
protein levels. Deviations in the levels of mRNA when compared to protein have been 
registered among many authors. [71, 72] But these results have largely been attributed to 
mRNA variations, post-transcriptional- and post-translational regulation, as well as errors in 
measurement. [72] 
Some results between mRNA and protein correlate very little. [73] Oscillations may be the 
reason for this. This sheds doubt on any modern technique using mRNA to study protein 
expression; results verified by such techniques are jeopardized. This includes examination of 
different expressed genes with microarray based mRNA expression systems that detects the 
expression of more than 40 000 different genes at a single time point. If all genes had similar 
fluctuations, approximately 25 percent of the genes will be within one of their peaks and show 
a peak-related expression level which may not reflect their effect on protein expression at all.   
Thus, conclusions based on mRNA expression studies must be supplied with protein 
expression assays, before the results can be trusted.  
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Part 6: Conclusions 
The presented hypothesis is that mRNA levels show periodical oscillations. We do not believe 
these to be stochastic, but a part of a cellular feedback system, perhaps regulated by miRNA. 
Several authors support the theory about fluctuations in mRNA concentrations and gene 
expression, though they do not entirely agree regarding the underlying causes and whether the 
occurrence is coincidental or regulatory.  
Although we have not yet found common ground regarding the mechanisms, we should all be 
able to accept its presence. The fluctuations in mRNA levels greatly complicate the research 
targeting gene expression. It also questions the validity of qPCR – a tool widely used for 
capturing snapshot events and uses this to draw conclusions about gene expression, protein 
synthesis and RNA levels. But if the mRNA fluctuates, the snapshots may depict an aberrant 
moment – a peak or it may depict a bottom – instead of a desired average. In either case, 
comparison between different cell lines, or even within one cell line, cannot hold any validity.   
If these results can be generalized and applied to most other mRNA expression behaviors, it is 
a paradigm shift, as mRNA quantification at a single time point may not reflect the amount of 
mRNA the cells translate nor the cells’ level of protein synthesis. Only further research may 
shed light upon this field. With this presented work, I would like to encourage this subject, 
mRNA oscillatory behavior, to be better and thoroughly studied, in the near future. 
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